Hemostemix (TSX V:HEM; OTCQB:HMTXF) is a clinical-stage biotechnology company focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases.
Hemostemix’s proprietary platform technology is based on more than 10 years of clinical data demonstrating the ability of our autologous cell product to regenerate diseased and damaged tissue. Our efficient, scalable and cost-effective platform has the potential to generate therapies for a broad range of ischemic diseases.
ACP-01, our lead clinical stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is currently in a Phase 2 clinical trial in Canada and the United States.
Welcome to Hemostemix Inc.
Your Fountain of Youth is your stem cells. Drawn from your blood, differentiated into our patented product and reintroduced into your heart, lungs, limb, by your physician seven days later, is ACP-01. As it forms new neovascularization, creating new circulation where the body signals it needs regeneration, ACP is Your Fountain of Youth. It’s why we globally trademarked “Your Fountain of Youth!”
Enjoy the journey. Join me, and join us, other management, the board and certain advisers, as shareholders! I think you’ll be very pleased you did in the fullness of time.
Thomas A. Smeenk
CEO & Cofounder